Royce & Associates’s Pacira BioSciences PCRX Stock Holding History

Royce & Associates’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6,803	Closed	-$209K	–	923
2023 Q3	$209K	Sell	6,803 -117,579	-95%	-$4.24M	﹤0.01%	873
2023 Q2	$4.98M	Buy	+124,382	New	+$5.14M	0.05%	493
2021 Q2	–	Sell	-115,157	Closed	-$8.07M	–	1036
2021 Q1	$8.07M	Sell	115,157 -41,933	-27%	-$3M	0.05%	501
2020 Q4	$9.4M	Buy	157,090 +3,647	+2%	+$214K	0.08%	388
2020 Q3	$9.22M	Sell	153,443 -11,857	-7%	-$689K	0.1%	303
2020 Q2	$8.67M	Buy	165,300 +164,426	+18,813%	+$6.87M	0.1%	304
2020 Q1	$29K	Buy	874 +58	+7%	+$2.41K	﹤0.01%	1072
2019 Q4	$37K	Sell	816 -244	-23%	-$10.4K	﹤0.01%	1067
2019 Q3	$40K	Buy	+1,060	New	+$42.3K	﹤0.01%	1075

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Royce & Associates's PCRX Position: Q4 2023 in Review

Royce & Associates sold out of Pacira BioSciences (PCRX) in Q4 2023, closing a stake of 6,803 shares — an estimated $209K sold.

Royce & Associates first reported a position in PCRX in Q3 2019 and held it in 9 quarters. The position peaked at $9.4M in Q4 2020. 261 funds tracked by Wall St. Rank hold PCRX as of Q4 2023.

Royce & Associates reported no remaining Pacira BioSciences position as of Q4 2023 after selling out during the quarter.
Royce & Associates sold 6,803 Pacira BioSciences shares in Q4 2023, an estimated $209K.
Royce & Associates first reported a position in Pacira BioSciences in Q3 2019 and held it in 9 quarters.
Royce & Associates's Pacira BioSciences position peaked at $9.4M in Q4 2020.
261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2023.

Based on Royce & Associates's 13F filing for Q4 2023, filed 12 Feb 2024.